274 related articles for article (PubMed ID: 22084065)
1. Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma.
Olson P; Chu GC; Perry SR; Nolan-Stevaux O; Hanahan D
Proc Natl Acad Sci U S A; 2011 Dec; 108(49):E1275-84. PubMed ID: 22084065
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib malate for the treatment of pancreas malignancies--where does it fit?
Mankal P; O'Reilly E
Expert Opin Pharmacother; 2013 Apr; 14(6):783-92. PubMed ID: 23458511
[TBL] [Abstract][Full Text] [Related]
3. Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models.
Singh M; Couto SS; Forrest WF; Lima A; Cheng JH; Molina R; Long JE; Hamilton P; McNutt A; Kasman I; Nannini MA; Reslan HB; Cao TC; Ho CC; Barck KH; Carano RA; Foreman O; Eastham-Anderson J; Jubb AM; Ferrara N; Johnson L
J Pathol; 2012 Aug; 227(4):417-30. PubMed ID: 22611036
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors.
Bisht S; Feldmann G; Brossart P
Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):777-88. PubMed ID: 23590356
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic Therapy in Pancreatic Neuroendocrine Tumors.
Capozzi M; VON Arx C; DE Divitiis C; Ottaiano A; Tatangelo F; Romano GM; Tafuto S;
Anticancer Res; 2016 Oct; 36(10):5025-5030. PubMed ID: 27798861
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic targeting of tumor-associated macrophages in pancreatic neuroendocrine tumors.
Krug S; Abbassi R; Griesmann H; Sipos B; Wiese D; Rexin P; Blank A; Perren A; Haybaeck J; Hüttelmaier S; Rinke A; Gress TM; Michl P
Int J Cancer; 2018 Oct; 143(7):1806-1816. PubMed ID: 29696624
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib in pancreatic neuroendocrine tumors.
Raymond E; Hammel P; Dreyer C; Maatescu C; Hentic O; Ruszniewski P; Faivre S
Target Oncol; 2012 Jun; 7(2):117-25. PubMed ID: 22661319
[TBL] [Abstract][Full Text] [Related]
8. Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib.
Faivre S; Ronot M; Dreyer C; Serrate C; Hentic O; Bouattour M; Bruno O; Couvelard A; Vilgrain V; Raymond E
Target Oncol; 2012 Jun; 7(2):127-33. PubMed ID: 22585430
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib paves the way for targeted therapies in neuroendocrine tumors.
Raymond E; Faivre S; Hammel P; Ruszniewski P
Target Oncol; 2009 Dec; 4(4):253-4. PubMed ID: 19911111
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib for advanced pancreatic neuroendocrine tumors.
Hubner RA; Valle JW
Expert Rev Anticancer Ther; 2011 Dec; 11(12):1817-27. PubMed ID: 22117148
[TBL] [Abstract][Full Text] [Related]
11. Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent Mechanism.
Wiedmer T; Blank A; Pantasis S; Normand L; Bill R; Krebs P; Tschan MP; Marinoni I; Perren A
Mol Cancer Ther; 2017 Nov; 16(11):2502-2515. PubMed ID: 28729403
[TBL] [Abstract][Full Text] [Related]
12. Nintedanib Is a Highly Effective Therapeutic for Neuroendocrine Carcinoma of the Pancreas (PNET) in the Rip1Tag2 Transgenic Mouse Model.
Bill R; Fagiani E; Zumsteg A; Antoniadis H; Johansson D; Haefliger S; Albrecht I; Hilberg F; Christofori G
Clin Cancer Res; 2015 Nov; 21(21):4856-67. PubMed ID: 26206868
[TBL] [Abstract][Full Text] [Related]
13. Severe perirenal hematoma in a patient with a single kidney treated with sunitinib for metastatic pancreatic neuroendocrine tumor.
Zugazagoitia J; Sastre J; Barrera J; García B; Díaz-Rubio E
J Cancer Res Ther; 2012; 8(2):303-5. PubMed ID: 22842382
[TBL] [Abstract][Full Text] [Related]
14. New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?
Raymond E; Ruszniewski P
Target Oncol; 2012 Jun; 7(2):91-2. PubMed ID: 22669625
[No Abstract] [Full Text] [Related]
15. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice.
Maione F; Capano S; Regano D; Zentilin L; Giacca M; Casanovas O; Bussolino F; Serini G; Giraudo E
J Clin Invest; 2012 May; 122(5):1832-48. PubMed ID: 22484816
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
17. The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer.
Martínez-Bosch N; Guerrero PE; Moreno M; José A; Iglesias M; Munné-Collado J; Anta H; Gibert J; Orozco CA; Vinaixa J; Fillat C; Viñals F; Navarro P
Oncotarget; 2016 Jul; 7(30):48265-48279. PubMed ID: 27374084
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive intravital high-resolution imaging of pancreatic neuroendocrine tumours.
Balan M; Trusohamn M; Ning FC; Jacob S; Pietras K; Eriksson U; Berggren PO; Nyqvist D
Sci Rep; 2019 Oct; 9(1):14636. PubMed ID: 31601958
[TBL] [Abstract][Full Text] [Related]
19. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.
Allen E; Walters IB; Hanahan D
Clin Cancer Res; 2011 Aug; 17(16):5299-310. PubMed ID: 21622725
[TBL] [Abstract][Full Text] [Related]
20. Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.
Tijeras-Raballand A; Neuzillet C; Couvelard A; Serova M; de Gramont A; Hammel P; Raymond E; Faivre S
Target Oncol; 2012 Sep; 7(3):173-81. PubMed ID: 22923165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]